Created by Citation bot
Last edited March 21, 2026
m Removed empty portal template using script
enhanced formatting per standard format and updated info
 
Line 2: Line 2:
{{Infobox scientist
{{Infobox scientist
| name              = Dipyaman Ganguly
| name              = Dipyaman Ganguly
| image            =
| image            = DGanguly.jpg
| alt              =  
| alt              =  
| caption          =  
| caption          =  
Line 9: Line 9:
| death_date        =  
| death_date        =  
| death_place      =  
| death_place      =  
| nationality      = [[Indian nationality|Indian]]
| fields            = {{ublist| [[Immunology]] | [[Cell biology]] }}
| fields            = {{ublist| [[Immunology]] | [[Cell biology]] |}}
| workplaces        = {{ublist | [[Ashoka University]] }}
| workplaces        = {{ublist | [[Indian Institute of Chemical Biology]] }}
| alma_mater        = {{ublist|Rahara Ramakrishna Mission Boys’ Home High School|[[Medical College and Hospital, Kolkata]] |[[Indian Institute of Chemical Biology]] | [[University of Texas MD Anderson Cancer Center]] | [[Columbia University Medical Center]] }}
| alma_mater        = {{ublist|[[Rahara Ramakrishna Mission Boys' Home High School|Rahara Ramakrishna Mission Boys’ Home High School]]|[[Medical College and Hospital, Kolkata]] |[[Indian Institute of Chemical Biology]] | [[University of Texas MD Anderson Cancer Center]] | [[Columbia University Medical Center]] }}
| doctoral_advisor  =  
| doctoral_advisor  =  
| doctoral_students =  
| doctoral_students =  
| known_for        = Studies on [[Immunology|Human Immunology]]
| known_for        = Studies on [[Immunology|Human Immunology]]
| awards            = {{ublist| 2013 [[Ramanujan Fellowship]] |2017 [[Swarnajayanti Fellowship]] | 2017 [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award | 2017/18 [[National Bioscience Award for Career Development|N-BIOS Prize]] | 2019 [[CDRI Award for Excellence in Drug Research]]| 2019 [[Merck Young Scientist Award]] }}  
| awards            = {{ublist| 2013 [[Ramanujan Fellowship]] |2017 [[Swarnajayanti Fellowship]] | 2017 [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award | 2017/18 [[National Bioscience Award for Career Development|N-BIOS Prize]] | 2019 [[CDRI Award for Excellence in Drug Research]]| 2019 [[Merck Young Scientist Award]]| 2022  [[Shanti Swarup Bhatnagar Prize]]}}  
}}
}}
'''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a Principal Scientist and Swarnajayanthi Fellow at the CSIR-[[Indian Institute of Chemical Biology]] (IICB).<ref name="Profile on SERB">{{Cite web |url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf |title=Profile on SERB |date=2018-12-27 |website=Scientific and Engineering Research Board |access-date=2018-12-27}}</ref> He heads the Dendritic Cell Laboratory of IICB, popularly known as Ganguly Lab, where he hosts several researchers involved in research on regulation of innate Immunity and pathogenesis of [[inflammatory disorders]].<ref name="DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab">{{Cite web |url=https://sites.google.com/site/dclabiicb/dclab-team |title=DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab |date=2018-12-27 |website=sites.google.com |access-date=2018-12-27}}</ref>
'''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a professor in the Department of Biology, [[Ashoka University]].<ref name="Profile on SERB">{{Cite web |url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf |title=Profile on SERB |date=2018-12-27 |website=Scientific and Engineering Research Board |access-date=2018-12-27}}</ref> The [[Council of Scientific and Industrial Research]], the apex agency of the Government of India for scientific research, awarded him the [[Shanti Swarup Bhatnagar Prize for Science and Technology]], one of the highest Indian science awards for his contributions to Medical Sciences in 2022.


Ganguly graduated in medicine from [[Medical College and Hospital, Kolkata]] in 2001 but shifted his focus to biomedical research and joined the [[Institute of Genomics and Integrative Biology]] as a clinical associate.<ref name="Profile on SERB" /> In 2003, he joined [[Indian Institute of Chemical Biology]] for doctoral research as a research scholar which earned him his first PhD in 2006. Moving to the US, he carried on his research at [[University of Texas MD Anderson Cancer Center]] and received another PhD from the [[University of Texas Health Science Center at Houston]].<ref name="IICB profile">{{Cite web |url=http://iicb.res.in/dipyaman-ganguly/ |title=IICB profile |date=2018-12-27 |website=Indian Institute of Chemical Biology |language=en-US |access-date=2018-12-27}}</ref> His post-doctoral work was at the [[Columbia University Medical Center]] as an SLE Foundation Fellow<ref>{{Cite web|url=http://www.eurekalert.org/pub_releases/2011-04/lri-slf040511.php|title=S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research|website=EurekAlert!|language=en|access-date=2019-07-10}}</ref> and on his return to India, he joined IICB where he is a Principal Scientist. He is also a Swarnajayanti Fellow of the [[Department of Science and Technology (India)|Department of Science and Technology]], and was formerly a Ramanujan Fellow of the [[Science and Engineering Research Board]] of the [[Department of Science and Technology (India)|Department of Science and Technology]].
Ganguly graduated in medicine from [[Medical College and Hospital, Kolkata]] in 2001 but shifted his focus to biomedical research and joined the [[Institute of Genomics and Integrative Biology]] as a clinical associate.<ref name="Profile on SERB" /> In 2003, he joined [[Indian Institute of Chemical Biology]] for doctoral research as a research scholar which earned him his first PhD in 2006. Moving to the US, he carried on his research at [[University of Texas MD Anderson Cancer Center]] and received another PhD from the [[University of Texas Health Science Center at Houston]].<ref name="IICB profile">{{Cite web |url=http://iicb.res.in/dipyaman-ganguly/ |title=IICB profile |date=2018-12-27 |website=Indian Institute of Chemical Biology |language=en-US |access-date=2018-12-27}}</ref> His post-doctoral work was at the [[Columbia University Medical Center]] as an SLE Foundation Fellow<ref>{{Cite web|url=http://www.eurekalert.org/pub_releases/2011-04/lri-slf040511.php|title=S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research.|website=EurekAlert!|language=en|access-date=2019-07-10}}</ref> He was also a Swarnajayanti Fellow of the [[Department of Science and Technology (India)|Department of Science and Technology]], and was formerly a Ramanujan Fellow of the [[Science and Engineering Research Board]] of the [[Department of Science and Technology (India)|Department of Science and Technology]].


== Scientific contribution ==
== Scientific contribution ==
Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal|last1=Liu|first1=Chinky Shiu Chen|last2=Raychaudhuri|first2=Deblina|last3=Paul|first3=Barnali|last4=Chakrabarty|first4=Yogaditya|last5=Ghosh|first5=Amrit Raj|last6=Rahaman|first6=Oindrila|last7=Talukdar|first7=Arindam|last8=Ganguly|first8=Dipyaman|date=2018-02-15|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation|journal=The Journal of Immunology|language=en|volume=200|issue=4|pages=1255–1260|doi=10.4049/jimmunol.1701118|pmid=29330322|issn=0022-1767|doi-access=free}}</ref>  They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/|title=Why the obese are prone to diabetes: a protein gives a clue|date=2016-09-26|website=The Indian Express|language=en-IN|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526|title=Obesity link to diabetes decoded|website=www.telegraphindia.com|language=en|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal|last1=Ganguly|first1=Dipyaman|last2=Chamilos|first2=Georgios|last3=Lande|first3=Roberto|last4=Gregorio|first4=Josh|last5=Meller|first5=Stephan|last6=Facchinetti|first6=Valeria|last7=Homey|first7=Bernhard|last8=Barrat|first8=Franck J.|last9=Zal|first9=Tomasz|date=2009-08-31|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|language=en|volume=206|issue=9|pages=1983–1994|doi=10.1084/jem.20090480|pmid=19703986|issn=0022-1007|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal|last=Bosch|first=Xavier|date=2011-08-25|title=Systemic Lupus Erythematosus and the Neutrophil|journal=New England Journal of Medicine|language=en|volume=365|issue=8|pages=758–760|doi=10.1056/NEJMcibr1107085|pmid=21864171|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases|date=2018-06-03|website=BioTech Times|language=en-US|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite journal|url=https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1/|title=Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomized control trial|year=2020|doi=10.1101/2020.11.25.20237883|last1=Ray|first1=Yogiraj|last2=Paul|first2=Shekhar Ranjan|last3=Bandopadhyay|first3=Purbita|last4=d'Rozario|first4=Ranit|last5=Sarif|first5=Jafar|last6=Lahiri|first6=Abhishake|last7=Bhowmik|first7=Debaleena|last8=Vasudevan|first8=Janani Srinivasa|last9=Maurya|first9=Ranjeet|last10=Kanakan|first10=Akshay|last11=Sharma|first11=Sachin|last12=Kumar|first12=Manish|last13=Singh|first13=Praveen|last14=Roy|first14=Rammohan|last15=Chaudhury|first15=Kausik|last16=Maiti|first16=Rajsekhar|last17=Bagchi|first17=Saugata|last18=Maiti|first18=Ayan|last19=Perwez|first19=Md. Masoom|last20=Mondal|first20=Abhinandan|last21=Tewari|first21=Avinash|last22=Mandal|first22=Samik|last23=Roy|first23=Arpan|last24=Saha|first24=Moumita|last25=Biswas|first25=Durba|last26=Maiti|first26=Chikam|last27=Chakraborty|first27=Sayantan|last28=Sarkar|first28=Biswanath Sharma|last29=Haldar|first29=Anima|last30=Saha|first30=Bibhuti|s2cid=227189790|display-authors=1}}</ref>
Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal|last1=Liu|first1=Chinky Shiu Chen|last2=Raychaudhuri|first2=Deblina|last3=Paul|first3=Barnali|last4=Chakrabarty|first4=Yogaditya|last5=Ghosh|first5=Amrit Raj|last6=Rahaman|first6=Oindrila|last7=Talukdar|first7=Arindam|last8=Ganguly|first8=Dipyaman|date=2018-02-15|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation|journal=The Journal of Immunology|language=en|volume=200|issue=4|pages=1255–1260|doi=10.4049/jimmunol.1701118|pmid=29330322|issn=0022-1767|doi-access=free}}</ref>  They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/|title=Why the obese are prone to diabetes: a protein gives a clue|date=2016-09-26|website=The Indian Express|language=en-IN|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526|title=Obesity link to diabetes decoded|website=www.telegraphindia.com|language=en|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal|last1=Ganguly|first1=Dipyaman|last2=Chamilos|first2=Georgios|last3=Lande|first3=Roberto|last4=Gregorio|first4=Josh|last5=Meller|first5=Stephan|last6=Facchinetti|first6=Valeria|last7=Homey|first7=Bernhard|last8=Barrat|first8=Franck J.|last9=Zal|first9=Tomasz|date=2009-08-31|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|language=en|volume=206|issue=9|pages=1983–1994|doi=10.1084/jem.20090480|pmid=19703986|issn=0022-1007|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal|last=Bosch|first=Xavier|date=2011-08-25|title=Systemic Lupus Erythematosus and the Neutrophil|journal=New England Journal of Medicine|language=en|volume=365|issue=8|pages=758–760|doi=10.1056/NEJMcibr1107085|pmid=21864171|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases|date=2018-06-03|website=BioTech Times|language=en-US|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite journal |last1=Ray |first1=Yogiraj |last2=Paul |first2=Shekhar Ranjan |last3=Bandopadhyay |first3=Purbita |last4=d'Rozario |first4=Ranit |last5=Sarif |first5=Jafar |last6=Lahiri |first6=Abhishake |last7=Bhowmik |first7=Debaleena |last8=Vasudevan |first8=Janani Srinivasa |last9=Maurya |first9=Ranjeet |last10=Kanakan |first10=Akshay |last11=Sharma |first11=Sachin |last12=Kumar |first12=Manish |last13=Singh |first13=Praveen |last14=Roy |first14=Rammohan |last15=Chaudhury |first15=Kausik |last16=Maiti |first16=Rajsekhar |last17=Bagchi |first17=Saugata |last18=Maiti |first18=Ayan |last19=Perwez |first19=Md. Masoom |last20=Mondal |first20=Abhinandan |last21=Tewari |first21=Avinash |last22=Mandal |first22=Samik |last23=Roy |first23=Arpan |last24=Saha |first24=Moumita |last25=Biswas |first25=Durba |last26=Maiti |first26=Chikam |last27=Chakraborty |first27=Sayantan |last28=Sarkar |first28=Biswanath Sharma |last29=Haldar |first29=Anima |last30=Saha |first30=Bibhuti |display-authors=1 |title=A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19 |journal=Nature Communications |date=2022 |volume=13 |issue=1 |article-number=383 |doi=10.1038/s41467-022-28064-7 |pmid=35046397 |pmc=8770561 |bibcode=2022NatCo..13..383R |medrxiv=10.1101/2020.11.25.20237883v1}}</ref>


== Awards ==
== Awards ==
The [[Department of Biotechnology]] of the Government of India awarded him the [[National Bioscience Award for Career Development]], one of the highest Indian science awards, for his contributions to biosciences, in 2017/18.<ref name="Awardees of National Bioscience Awards for Career Development">{{Cite web |url=http://dbtindia.nic.in/wp-content/uploads/2014/03/list_of_bioscience_awardees.pdf |title=Awardees of National Bioscience Awards for Career Development |date=2016 |publisher=Department of Biotechnology |access-date=2017-11-20}}</ref> He is also a recipient of the Merck Young Scientist Award, the CDRI Award for Excellence in Drug Research from CSIR-[[Central Drug Research Institute]], Swarnajayanthi Fellowship of the [[Department of Science and Technology (India)|Department of Science and Technology]] and the [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award of the [[Elsevier]].<ref name="Scopus Award 2017">{{Cite web |url=http://southasia.elsevier.com/ElsevierDNN/ScopusAward2017/tabid/3051/Default.aspx |title=Scopus Award 2017 |date=2018-12-27 |website=southasia.elsevier.com |access-date=2018-12-27}}</ref>
The [[Department of Biotechnology]] of the Government of India awarded him the [[National Bioscience Award for Career Development]], one of the highest Indian science awards, for his contributions to biosciences, in 2017/18.<ref name="Awardees of National Bioscience Awards for Career Development">{{Cite web |url=http://dbtindia.nic.in/wp-content/uploads/2014/03/list_of_bioscience_awardees.pdf |title=Awardees of National Bioscience Awards for Career Development |date=2016 |publisher=Department of Biotechnology |access-date=2017-11-20 |archive-date=4 March 2018 |archive-url=https://web.archive.org/web/20180304191331/http://dbtindia.nic.in/wp-content/uploads/2014/03/list_of_bioscience_awardees.pdf |url-status=dead }}</ref> He is also a recipient of the Merck Young Scientist Award, the CDRI Award for Excellence in Drug Research from CSIR-[[Central Drug Research Institute]], Swarnajayanthi Fellowship of the [[Department of Science and Technology (India)|Department of Science and Technology]] and the [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award of the [[Elsevier]].<ref name="Scopus Award 2017">{{Cite web |url=http://southasia.elsevier.com/ElsevierDNN/ScopusAward2017/tabid/3051/Default.aspx |title=Scopus Award 2017 |date=2018-12-27 |website=southasia.elsevier.com |access-date=2018-12-27}}</ref> He was awarded the [[Shanti Swarup Bhatnagar Prize]] for Science and Technology in Medical Sciences in the year 2022.


== Public outreach ==
== Public outreach ==
Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web|url=http://dialogue.ias.ac.in/|title=DIALOGUE - Science, Scientists, and Society|website=Dialogue|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs|title=Are we reaching the 'public' with our public outreach programs?|date=2018-07-13|website=IndiaBioscience|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health.<ref>{{Cite web|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550|title=One pandemic unmasking another}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece|title=More 'strain' on Covid management|date=12 January 2021 }}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece|title=Slow mutation of the Covid pandemic|date=9 February 2021 }}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html|title=Pandemic will end up as an endemic}}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html|title=Herd immunity may come before COVID-19 vaccine}}</ref>
Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web|url=http://dialogue.ias.ac.in/|title=DIALOGUE - Science, Scientists, and Society|website=Dialogue|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs|title=Are we reaching the 'public' with our public outreach programs?|date=2018-07-13|website=IndiaBioscience|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health.<ref>{{Cite web|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550|title=One pandemic unmasking another}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece|title=More 'strain' on Covid management|date=12 January 2021 }}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece|title=Slow mutation of the Covid pandemic|date=9 February 2021 }}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html|title=Pandemic will end up as an endemic|date=21 April 2021 }}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html|title=Herd immunity may come before COVID-19 vaccine|date=26 July 2020 }}</ref>


== Selected bibliography ==
== Selected bibliography ==
Line 52: Line 51:
* [[Dendritic cell]]
* [[Dendritic cell]]
{{div col end}}
{{div col end}}
 
{{Portal|India|Biology|Biography}}


== Notes ==
== Notes ==
Line 64: Line 63:


{{N-BIOS Laureates 2010–2019}}
{{N-BIOS Laureates 2010–2019}}
{{authority control}}


{{DEFAULTSORT:Ganguly, Dipyaman}}
{{DEFAULTSORT:Ganguly, Dipyaman}}
[[Category:Indian scientific authors]]
[[Category:Year of birth missing (living people)]]
[[Category:Year of birth missing (living people)]]
[[Category:N-BIOS Prize recipients]]
[[Category:N-BIOS Prize recipients]]
Line 77: Line 77:
[[Category:Living people]]
[[Category:Living people]]
[[Category:Scientists from West Bengal]]
[[Category:Scientists from West Bengal]]
[[Category:Academic staff of Ashoka University]]

Latest revision as of 03:39, 21 March 2026

Dipyaman Ganguly
Born25 October
Alma mater
Known forStudies on Human Immunology
Awards
Scientific career
Fields
Institutions

Dipyaman Ganguly is an Indian physician-scientist immunologist and cell biologist, currently a professor in the Department of Biology, Ashoka University.[1] The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Medical Sciences in 2022.

Ganguly graduated in medicine from Medical College and Hospital, Kolkata in 2001 but shifted his focus to biomedical research and joined the Institute of Genomics and Integrative Biology as a clinical associate.[1] In 2003, he joined Indian Institute of Chemical Biology for doctoral research as a research scholar which earned him his first PhD in 2006. Moving to the US, he carried on his research at University of Texas MD Anderson Cancer Center and received another PhD from the University of Texas Health Science Center at Houston.[2] His post-doctoral work was at the Columbia University Medical Center as an SLE Foundation Fellow[3] He was also a Swarnajayanti Fellow of the Department of Science and Technology, and was formerly a Ramanujan Fellow of the Science and Engineering Research Board of the Department of Science and Technology.

Scientific contribution[edit | edit source]

Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.[4] They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.[5][6] Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,[7] as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,[8] which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.[9] Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.[10]

Awards[edit | edit source]

The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2017/18.[11] He is also a recipient of the Merck Young Scientist Award, the CDRI Award for Excellence in Drug Research from CSIR-Central Drug Research Institute, Swarnajayanthi Fellowship of the Department of Science and Technology and the NASI-Scopus Young Scientist Award of the Elsevier.[12] He was awarded the Shanti Swarup Bhatnagar Prize for Science and Technology in Medical Sciences in the year 2022.

Public outreach[edit | edit source]

Ganguly is an enthusiast for public outreach of science in India,[13][14] an avid stargazer and a public commentator and popular columnist on issues on science and health.[15][16][17][18][19][20][21][22]

Selected bibliography[edit | edit source]

See also[edit | edit source]

Notes[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "Profile on SERB" (PDF). Scientific and Engineering Research Board. 27 December 2018. Retrieved 27 December 2018.
  2. "IICB profile". Indian Institute of Chemical Biology. 27 December 2018. Retrieved 27 December 2018.
  3. "S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research". EurekAlert!. Retrieved 10 July 2019.
  4. Liu, Chinky Shiu Chen; Raychaudhuri, Deblina; Paul, Barnali; Chakrabarty, Yogaditya; Ghosh, Amrit Raj; Rahaman, Oindrila; Talukdar, Arindam; Ganguly, Dipyaman (15 February 2018). "Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation". The Journal of Immunology. 200 (4): 1255–1260. doi:10.4049/jimmunol.1701118. ISSN 0022-1767. PMID 29330322.
  5. "Why the obese are prone to diabetes: a protein gives a clue". The Indian Express. 26 September 2016. Retrieved 10 July 2019.
  6. "Obesity link to diabetes decoded". www.telegraphindia.com. Retrieved 10 July 2019.
  7. Ganguly, Dipyaman; Chamilos, Georgios; Lande, Roberto; Gregorio, Josh; Meller, Stephan; Facchinetti, Valeria; Homey, Bernhard; Barrat, Franck J.; Zal, Tomasz (31 August 2009). "Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8". The Journal of Experimental Medicine. 206 (9): 1983–1994. doi:10.1084/jem.20090480. ISSN 0022-1007. PMC 2737167. PMID 19703986.
  8. Bosch, Xavier (25 August 2011). "Systemic Lupus Erythematosus and the Neutrophil". New England Journal of Medicine. 365 (8): 758–760. doi:10.1056/NEJMcibr1107085. ISSN 0028-4793. PMID 21864171.
  9. "IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases". BioTech Times. 3 June 2018. Retrieved 10 July 2019.
  10. Ray, Yogiraj; et al. (2022). "A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19". Nature Communications. 13 (1) 383. Bibcode:2022NatCo..13..383R. doi:10.1038/s41467-022-28064-7. medRxiv 10.1101/2020.11.25.20237883v1. PMC 8770561. PMID 35046397.
  11. "Awardees of National Bioscience Awards for Career Development" (PDF). Department of Biotechnology. 2016. Archived from the original (PDF) on 4 March 2018. Retrieved 20 November 2017.
  12. "Scopus Award 2017". southasia.elsevier.com. 27 December 2018. Retrieved 27 December 2018.
  13. "DIALOGUE - Science, Scientists, and Society". Dialogue. Retrieved 10 July 2019.
  14. "Are we reaching the 'public' with our public outreach programs?". IndiaBioscience. 13 July 2018. Retrieved 10 July 2019.
  15. "Coronavirus: the fight & the soldiers".
  16. "Preparing for long-lasting Covid".
  17. "One pandemic unmasking another".
  18. "Will the vaccines protect us from new strains of the novel coronavirus?".
  19. "More 'strain' on Covid management". 12 January 2021.
  20. "Slow mutation of the Covid pandemic". 9 February 2021.
  21. "Pandemic will end up as an endemic". 21 April 2021.
  22. "Herd immunity may come before COVID-19 vaccine". 26 July 2020.

External links[edit | edit source]